<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590275</url>
  </required_header>
  <id_info>
    <org_study_id>HOPE</org_study_id>
    <nct_id>NCT03590275</nct_id>
  </id_info>
  <brief_title>Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX</brief_title>
  <acronym>HOPE</acronym>
  <official_title>Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Pisana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify new prognostic factors in patients affected by advanced
      pancreatic carcinoma treated with first line chemotherapy with FOLFIRINOX regimen. Primary
      objective is the identification of clinical, laboratory and pathologic factors affecting
      overall survival of these patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 18, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall survival is defined as the time from study entry until death from any cause. Patients who are alive at the end of the study will be censored at that point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression-free survival is defined as time from study entry until progression of disease (according to RECIST 1.1) or death from any cause. Patients who are alive without having progressed at the end of the study will be censored at their last radiological assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Response rate is defined as the fraction of treated patients who achieve a response as defined according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria vers. 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Toxicity Rate is defined as the percentage of patients, relative to the total of enrolled subjects, experiencing treatment-related adverse events as assessed by National Cancer Institute Common Toxicity Criteria (version 4.0), during chemotherapy.</description>
  </secondary_outcome>
  <enrollment type="Actual">343</enrollment>
  <condition>Pancreatic Cancer Non-resectable</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <description>Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with unresectable advanced pancreatic carcinoma treated with FOLFIRINOX at the
        involved institutions between 2010 and 2017 will be included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18 years

          -  citologically or histologically confirmed pancreatic carcinoma

          -  disease stage III or IV according to the American Joint Committee on Cancer (AJCC)
             staging system

          -  access to clinical informations collected before first-line starting

          -  availability of objective response evaluation and survival data

          -  written informed consent

        Exclusion Criteria:

          -  diagnosis of other neoplasia than pancreatic carcinoma

          -  treatment with drugs other than FOLFIRINOX

          -  treatment with experimental drugs in combination with FOLFIRINOX

          -  unavailability of clinical and pathological data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Fornaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero, Universitaria Pisana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncologia ASL BI</name>
      <address>
        <city>Ponderano</city>
        <state>Biella</state>
        <zip>13875</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS</name>
      <address>
        <city>Meldola</city>
        <state>Forl√¨ Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia FPO - IRCSS</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL VCO, Ospedale Castelli Verbania</name>
      <address>
        <city>Verbania</city>
        <state>Torino</state>
        <zip>28922</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica</name>
      <address>
        <city>Pisa</city>
        <zip>56012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. Molinette Oncologia 1</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Pisana</investigator_affiliation>
    <investigator_full_name>Alfredo Falcone</investigator_full_name>
    <investigator_title>Prof. Alfredo Falcone</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>FOLFIRINOX</keyword>
  <keyword>prognostic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

